A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study

BACKGROUND: It is 1 of the standard treatment options for metastasis pancreatic cancer to receive nab-paclitaxel (125 mg/m(2)) plus gemcitabine (1000 mg/m(2)) on days 1, 8 and 15 every 28 days. Some patients showed intolerance and inconvenience to this therapeutic regimen. Thus, we conducted this re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chen, Meng, Lingwei, Li, Xiaofen, Cheng, Ke, Yi, Cheng, Peng, Bing, Ma, Ji, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Hope In Despair - New Progress in The Diagnosis and Treatment of Pancreatic Cancer Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703471/
https://www.ncbi.nlm.nih.gov/pubmed/36423238
http://dx.doi.org/10.1177/10732748221141233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703471/
https://www.ncbi.nlm.nih.gov/pubmed/36423238
http://dx.doi.org/10.1177/10732748221141233

Ejemplares similares